Pfizer Inc.

Novo Nordisk A/S

Pharma companies squabble over a promising startup in the market for weight management products

Pfizer sues Novo Nordisk and Metsera - Oninvest

Eli Lilly and Company

Danish Novo Nordisk will release its quarterly report on Nov. 5.

Novo Nordisk's 5 challenges: what's at the center of investment banks' attention 

Novo Nordisk has entered into a battle with Pfizer over Metsera. Why do they want this biotech startup?

HSBC Holdings plc

Novartis AG

Japan's Nikkei index crossed the 50,000-point mark for the first time amid optimism in anticipation of U.S.-China talks and a rebound on Wall Street. Novartis buys biotech Avidity Biosciences for $12 billion, strengthening its position in RNAi therapeutics. HSBC pledges $1.1 billion in reserves after a failed Madoff judgment in Luxembourg. These and other topics - in our review of key events by the morning of October 27.

Highlights for the morning: Nikkei record, Novartis deal and the new role of bitcoin miners

Abbott Laboratories

Air Products and Chemicals, Inc.

Johnson & Johnson

Generac Holdings Inc.

ITT Inc.

Marex Group plc

Amazon.com, Inc.

GitLab Inc.

NVR, Inc.

Barrick Mining Corporation

Anglo American plc

Sibanye Stillwater Limited

AI is a risky strategy, real production is a conservative one: Oninvest asked Astero Falcon portfolio manager Alena Nikolaeva where to invest $10,000 if the horizon is about a year and the goal is to increase capital. Two strategies include companies from the "old" economy.

Where to invest $10,000 right now: the renaissance of real manufacturing 

AstraZeneca PLC

Daiichi Sankyo Company, Limited

The Enhertu drug was found to be more effective than a drug from Swiss Roche

AstraZeneca's drug has produced positive results in the fight against breast cancer. What about the stock?

The retail price of Ozempic, which Trump has called a "weight-loss drug," is about $1,000 for a one-month course

Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell

Akero Therapeutics, Inc.


The maker of Ozempic and Wegovy makes its first major deal under new CEO Mike Doustdar

Liver drugmaker Akero to be acquired by Novo Nordisk; shares soar 17%

The share price appreciation is giving Wall Street confidence that after a prolonged "winter" in biotech is finally beginning to thaw

Biotech stocks have revived after five years of stagnation. Why is growth far from complete?

NIKE, Inc.

Spotify Technology S.A.

CoreWeave, Inc.

UiPath, Inc.

Alcoa Corporation

Paychex, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: focus on the aftermath of the U.S. government shutdown

Merck & Co., Inc.

Pfizer received a three-year reprieve from 100 percent duties on drug imports in exchange for lower prices

Pfizer struck a price deal with the White House. Shares soared 6%

The bank doubts that the active ingredient in Ozempic and Wegovy will prove effective in fighting Alzheimer's disease

Pharmaceutical Companies